Archive for the ‘biotech/medical’ category: Page 72
Sep 20, 2024
DNA Computing Evolves: New System Stores Data, Plays Chess, and Solves Sudoku Puzzles
Posted by Jose Ruben Rodriguez Fuentes in categories: biotech/medical, computing, neuroscience
Last month, a team from North Carolina State University and Johns Hopkins University found a workaround. They embedded DNA molecules, encoding multiple images, into a branched gel-like structure resembling a brain cell.
Dubbed “dendricolloids,” the structures stored DNA files far better than those freeze-dried alone. DNA within dendricolloids can be repeatedly dried and rehydrated over roughly 170 times without damaging stored data. According to one estimate, each DNA strand could last over two million years at normal freezer temperatures.
Unlike previous DNA computers, the data can be erased and replaced like memory on classical computers to solve multiple problems—including a simple chess game and sudoku.
Sep 20, 2024
FDA approves Rybrevant for advanced lung cancer
Posted by Paul Battista in category: biotech/medical
The FDA approved amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to the agent’s manufacturer.
The indication applies to adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R substitution mutations whose disease progressed on or following treatment with an EGFR tyrosine kinase inhibitor.
Amivantamab-vmjw (Rybrevant, Janssen) is an EGFR and mesenchymal epithelial transition (MET) factor bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.
Sep 20, 2024
Scientists Identify New Blood Group After a 50 Year Mystery
Posted by Genevieve Klien in categories: biotech/medical, innovation
Sep 20, 2024
Sickle Cell Patient Cured With CRISPR Summits Kilimanjaro, Setting World Record
Posted by Quinn Sena in categories: biotech/medical, business, genetics
Four years after being functionally cured of sickle cell disease with a CRISPR gene-editing therapy, Jimi Olaghere has set a new world record for patients with this chronic and deadly disease.
Olaghere, a 39-year-old business owner from Atlanta, became the world’s first patient with sickle cell disease to reach the summit of Kilimanjaro at 7:30 am Tanzania time on Sept. 16. It’s the highest peak in Africa at 19,341 feet above sea level.
Sep 20, 2024
Epidemiology and socioeconomic correlates of brain and central nervous system cancers in Asia in 2020 and their projection to 2040
Posted by The Neuro-Network in categories: biotech/medical, neuroscience
Summery:
(
Mousavi, S., Seyedmirzaei, H., Shahrokhi Nejad, S. et al. Sci Rep 14, 21,936 (2024). https://doi.org/10.1038/s41598-024-73277-z.
Sep 20, 2024
Surgery-free Neuralink rival enables thought-controlled smart home
Posted by Shailesh Prasad in categories: biotech/medical, robotics/AI
Neurotech company Synchron has been making massive strides over the past couple of years. It’s just announced that a trial participant has used its brain-computer interface (BCI) to turn on the lights in his home, see who is at the door, and choose what to watch on the TV – hands-free and without even a voice command.
That’s thanks to Synchron’s interface translating his thoughts into commands relayed to Amazon’s Alexa service. The virtual assistant is set up on his tablet and connected to his smart home devices. The trial participant, who is living with amyotrophic lateral sclerosis (ALS) and can’t use his hands, can simply think about navigating through options displayed on the tablet to engage them.
Continue reading “Surgery-free Neuralink rival enables thought-controlled smart home” »
Sep 20, 2024
Brains Could Help Solve a Fundamental Problem in Computer Engineering
Posted by Dan Breeden in categories: biotech/medical, finance, mobile phones, quantum physics, robotics/AI
In recent years, these technological limitations have become far more pressing. Deep neural networks have radically expanded the limits of artificial intelligence—but they have also created a monstrous demand for computational resources, and these resources present an enormous financial and environmental burden. Training GPT-3, a text predictor so accurate that it easily tricks people into thinking its words were written by a human, costs $4.6 million and emits a sobering volume of carbon dioxide—as much as 1,300 cars, according to Boahen.
With the free time afforded by the pandemic, Boahen, who is faculty affiliate at the Wu Tsai Neurosciences Institute at Stanford and the Stanford Institute for Human-Centered AI (HAI), applied himself single mindedly to this problem. “Every 10 years, I realize some blind spot that I have or some dogma that I’ve accepted,” he says. “I call it ‘raising my consciousness.’”
This time around, raising his consciousness meant looking toward dendrites, the spindly protrusions that neurons use to detect signals, for a completely novel way of thinking about computer chips. And, as he writes in Nature, he thinks he’s figured out how to make chips so efficient that the enormous GPT-3 language prediction neural network could one day be run on a cell phone. Just as Feynman posited the “quantum supremacy” of quantum computers over traditional computers, Boahen wants to work toward a “neural supremacy.”
Sep 20, 2024
Every single member of the board just resigned from DNA tester 23andMe
Posted by Genevieve Klien in category: biotech/medical
Following a monthslong battle over CEO Anne Wojcicki’s plans to https://www.sec.gov/Archives/edgar/data/1804591/000134100424000072/sc13da1.htm” rel=“noopener”>take 23andMe private, all seven independent members of its board https://investors.23andme.com/news-releases/news-release-det...oard?_gl=1*1eip6nf*_ga*MTI2OTU3NjA4NC4xNzI2NjYwNzU5*_ga_G330GF3ZFF*MTcyNjY2MDc1OS4xLjEuMTcyNjY2MDgyNy4wLjAuMA…" rel="noopener">resigned en masse Tuesday.
The move is almost certainly the final nail in the coffin for the embattled company known for its mail-order DNA-testing kit. Since https://www.bloomberg.com/news/articles/2021-02-04/2…on-merger” rel=“noopener”>going public via merger with a special purpose acquisition company (SPAC) in 2021, 23andMe has never turned a profit. Its price on IPO day was $10; so far in 2024, it has yet to reach a $1 valuation. Following the resignation of all its independent directors Tuesday, the stock fell to its rock bottom: $0.30. (As of midday Wednesday, it’s back to $0.36.)
The board includes Sequoia Capital’s https://fortune.com/2024/07/25/seqouia-capital-roelof-botha-…e-nvidia/”>Roelof Botha as well as https://fortune.com/2023/02/28/why-youtube-betting-neal-moha…time-ceo/”>Neal Mohan, who took the helm as CEO of https://fortune.com/company/youtube/”>YouTube last year after Susan Wojcicki, Anne’s late sister, https://blog.youtube/inside-youtube/a-personal-update-from-susan/” rel=“noopener”>stepped down.
Sep 19, 2024
Human genome stored on ‘everlasting’ memory crystal
Posted by Dan Breeden in categories: biotech/medical, existential risks
The technology could also be used to create an enduring record of the genomes of endangered plant and animal species faced with extinction.
Eternity crystals
The 5D memory crystal was developed by the University of Southampton’s Optoelectronics Research Center (ORC).